Status:

COMPLETED

Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)

Lead Sponsor:

Peking Union Medical College Hospital

Conditions:

Acute Ischemic Stroke

Eligibility:

All Genders

40-80 years

Phase:

PHASE3

Brief Summary

AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular diseases. Pharmacological experiments confirmed that AngongNiuhuang pill can protect blood-brain barrier, inhibit capi...

Detailed Description

This trial is a prospective, randomized, double-blinded, placebo parallel controlled, multicenter trial. Patients who met the inclusion and exclusion criteria will be randomized 1:1 into two groups af...

Eligibility Criteria

Inclusion

  • Male or female participates aged 40-80 years.
  • Diagnosis with acute ischemic stroke.
  • Diagnosis with acute cerebral infarctions of internal carotid artery system.
  • 10≤ Baseline NIHSS \<20.
  • Time of onset ≤36h.
  • Provision of informed consent.

Exclusion

  • Not suitable for taking this medicine according to the judgement of consulting traditional Chinese medical doctor.
  • Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other brain organic diseases.
  • Patients with hemorrhagic transformation after cerebral infarction.
  • Received or planned to receive endovascular treatment, including thrombectomy, ultra early thrombectomy and stenting.
  • Received or planned to receive decompression craniectomy.
  • With mRS score \>1 before onset of this episode.
  • Participates who cannot tolerate the MRI scans, such as Using a pacemaker or automatic defibrillator or having claustrophobia.
  • With thrombocytopenia (\<100 x10\^9/L), hematologic diseases or other systemic bleeding tendency.
  • With Alanine transaminase or Aspartate aminotransferase \>1.5 times than normal upper limit or Creatinine \>1.5 times than normal upper limit.
  • Allergic to ingredients of AngongNiuhuang pill.
  • Received AngongNiuhuang pill within 1 month.
  • Participates who plan to become pregnant within 3 months, or women of childbearing age with negative pregnancy test but refuse to accept contraception; during pregnancy or lactation.
  • Participates in other clinical trials within 30 days before randomization or currently involved in other clinical trails.
  • Participates with a life expectancy less than 3 months.
  • Incapable to follow this study due to mental illness, cognitive or emotional disorders.
  • Participates are not eligible for this clinical trial as evaluated by the investigators.

Key Trial Info

Start Date :

October 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 30 2022

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT04475328

Start Date

October 1 2020

End Date

July 30 2022

Last Update

September 11 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Neurology,Peking Union Medical College Hospital,Shuaifuyuan 1,Dong Cheng District. Beijing

Beijing, Beijing Municipality, China, 100730

Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL) | DecenTrialz